Ligand Pharmaceuticals Incorporated (LGNZZ)

Market Cap	2.17B
Revenue (ttm)	181.49M
Net Income (ttm)	-132.62M
Shares Out	n/a
EPS (ttm)	-7.11
PE Ratio	n/a
Forward PE	18.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,400
Average Volume	5,568
Open	0.1200
Previous Close	n/a
Day's Range	0.1200 - 0.1200
52-Week Range	0.1169 - 0.1960
Beta	0.71
RSI	41.32
Earnings Date	Aug 6, 2025

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1987
• Employees: 68
• Stock Exchange: OTCMKTS
• Ticker Symbol: LGNZZ